2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Genomic Biomarkers: Role in personalized medicine and targeted therapies.
Genomic biomarkers are transforming cancer care by enabling precise, personalized treatment approaches. These biomarkers, derived from genetic, epigenetic, or molecular changes in tumors, help predict disease progression, treatment response, and patient outcomes. For instance, mutations in genes like EGFR or ALK in lung cancer guide the use of targeted therapies that block specific pathways, enhancing efficacy and reducing side effects. Biomarkers are also critical in identifying patients likely to benefit from immunotherapies, such as PD-L1 expression or microsatellite instability (MSI) status. Advances in high-throughput sequencing technologies have expanded the scope of biomarker discovery, allowing for the identification of novel targets and the development of companion diagnostics. As research progresses, integrating genomic biomarkers into routine clinical practice continues to refine therapeutic strategies, improve survival rates, and bring us closer to the promise of precision oncology.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China